Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported EBT for 14 consecutive years, with -$184.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 22.67% year-over-year to -$184.0 million; the TTM figure through Mar 2026 stood at -$599.2 million (down 10.4% YoY), while the FY2025 annual figure was -$565.0 million, changed 0.36% from the prior year.
• EBT retreated to -$184.0 million in Q1 2026 per RARE's latest filing, from -$121.7 million in the prior quarter.
• Across five years, EBT topped out at -$114.0 million in Q2 2025 and bottomed at -$238.8 million in Q3 2022.
• Historically, EBT has averaged -$154.3 million across 5 years, with a median of -$153.3 million in 2022.
• Annual changes were most pronounced in 2022 — EBT tumbled 227.98% — and 2023, when it jumped 33.42%.
• Ultragenyx Pharmaceutical's EBT stood at -$153.3 million in 2022, then gained by 16.87% to -$127.4 million in 2023, then decreased by 1.09% to -$128.8 million in 2024, then rose by 5.54% to -$121.7 million in 2025, then tumbled by 51.21% to -$184.0 million in 2026.
• Business Quant data shows RARE's EBT at -$184.0 million in Q1 2026, -$121.7 million in Q4 2025, and -$179.5 million in Q3 2025.